PENTA 9

HIV-1 Drug Resistance and Second-line Treatment in Children Randomized to Switch at Low versus Higher RNA Thresholds

18 Sep, 2015

Authors: Harrison L, Melvin A, Fiscus S, et al. For PENPACT-1 (PENTA 9PACTG 390) Study Team. Published in: JAIDS 2015;70(1):42-53 Background The PENPACT-1 trial compared virologic thresholds to determine when to switch…
Read More

Using CD4 Percentage and Age to Optimize Pediatric Antiretroviral Therapy Initiation

18 Apr, 2014

Authors: Yin D., Warshaw M., Miller W., Castro H., Fiscus S., Harper L., Harrison L., Klein N., Lewis J., Melvin A., Tudor-Williams G., McKinney R. Published in: Pediatrics, 2014;134(4):e1104-16 Background Quantifying…
Read More

HIV-1 resistance after randomized virologic switch at 1,000 or 30,000 c/ml in children.

18 Mar, 2014

Authors: Harrison L, Gibb DM, Fiscus S, Saïdi Y, Nastouli E, Harper L, Compagnucci A, Babiker A, Melvin A, Tudor-Williams G and the PENPACT 1 (PENTA 9/PACTG 390) Study Team.…
Read More

First-line antiretroviral therapy initiation with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIV-infected children: an open randomised controlled phase 2/3 trial.

18 Apr, 2011

Authors: The PENPACT-1 (PENTA 9 / PACTG 390) Study Team. Published in: Lancet Infectious Diseases. April: 2011, 273-283 Background Children with HIV will be on antiretroviral therapy (ART) longer than adults, and therefore the…
Read More

PENTA and IMPAACT: A phase II/III randomised, open-label trial of combination antiretroviral regimens and treatment-switching strategies in HIV-1-infected antiretroviral naïve children

18 Apr, 2010

PENTA and IMPAACT: A phase II/III randomised, open-label trial of combination antiretroviral regimens and treatment-switching strategies in HIV-1-infected antiretroviral naïve children Published in: XVIII International AIDS Conference, 22nd July 2010,…
Read More

Choice of first-line ART regimen in PENPACT 1: a randomized trial of combination antiretroviral regimens and treatment switching strategies in antiretroviral naive children >30 days and <18 years of age.

18 Jul, 2004

Authors: Gibb DM, Melvin A, Compagnucci A, McKinney R, Tudor-Williams G, Walker AS, Harper L, Hodge J, Powell C, Green H, Saïdi Y, Ortiz AA, Toye M, Girard S, Mofenson…
Read More